Allianz Biotechnologie - A - EUR/  DE0008481862  /

The Fund aims to generate long-term capital growth. We invest at least 70% of the Fund"s assets directly or via derivatives in equities and comparable securities of companies whose principal activity is researching, developing and producing biotechnological goods, processes or services. We may invest up to 10% of the Fund"s assets in Chinese A-shares. Moreover, investments can also be made in other equities and comparable securities. Up to 30% of the Fund"s assets may also be invested in money market instruments or bank deposits. A maximum of 10% of the Fund"s assets may be invested in target funds (UCITS and/or UCI). We pursue an active management approach aimed at outperforming the benchmark. The benchmark index is used for performance measurement purposes only and not for the purpose of portfolio composition. The majority of the securities included in the Fund are also included in the benchmark index. The fund manager has the flexibility to invest in securities that are not included in the benchmark index. When selecting and weighting the Fund's assets, Fund Management may deviate significantly from the securities included in the benchmark index, as well as their corresponding weightings. Benchmark: NASDAQ Biotechnology Price (in EUR).

The Fund aims to generate long-term capital growth. We invest at least 70% of the Fund"s assets directly or via derivatives in equities and comparable securities of companies whose principal activity is researching, developing and producing biotechnological goods, processes or services. We may invest up to 10% of the Fund"s assets in Chinese A-shares. Moreover, investments can also be made in other equities and comparable securities. Up to 30% of the Fund"s assets may also be invested in money market instruments or bank deposits. A maximum of 10% of the Fund"s assets may be invested in target funds (UCITS and/or UCI).